INVESTMENTS IN AFFILIATES, AVAILABLE-FOR-SALE EQUITY SECURITIES	3 Months Ended
Mar. 31, 2013
INVESTMENTS IN AFFILIATES, AVAILABLE-FOR-SALE EQUITY SECURITIES	3. INVESTMENTS IN AFFILIATES, AVAILABLE-FOR-SALE EQUITY SECURITIES Substantially all of the Company’s available-for-sale equity securities are shares of Chimera Investment Corporation (“Chimera”) and CreXus and are reported at fair value. The Company owned approximately 45.0 million shares of Chimera at a fair value of approximately $143.5 million at March 31, 2013 and approximately 45.0 million shares of Chimera at a fair value of approximately $117.4 million at December 31, 2012. At March 31, 2013 and December 31, 2012, the investment in Chimera had an unrealized gain of $4.6 million and an unrealized loss of $21.5 million, respectively. The Company owned approximately 9.5 million shares of CreXus at a fair value of approximately $124.1 million at March 31, 2013 and approximately 9.5 million shares of CreXus at a fair value of approximately $116.7 million at December 31, 2012. At March 31, 2013 and December 31, 2012, the investment in CreXus had an unrealized loss of $1.4 million and an unrealized loss of $8.7 million, respectively. The Company has evaluated the near-term prospects of its investment in affiliates in relation to the severity and length of time of the impairment. Based on this evaluation, management has determined that its investment in affiliates is not considered to be other-than-temporarily impaired as of March 31, 2013 and December 31, 2012 as the Company has the intent and ability to retain its investments for a period of time sufficient to allow for any anticipated recovery in market value.

INVESTMENTS IN AFFILIATES, AVAILABLE-FOR-SALE EQUITY SECURITIES

3 Months Ended

Mar. 31, 2013

INVESTMENTS IN AFFILIATES, AVAILABLE-FOR-SALE EQUITY SECURITIES

3. INVESTMENTS IN AFFILIATES, AVAILABLE-FOR-SALE EQUITY SECURITIES

Substantially all of the Company’s available-for-sale equity securities are shares of Chimera Investment Corporation (“Chimera”) and CreXus and are reported at fair value. The Company owned approximately 45.0 million shares of Chimera at a fair value of approximately $143.5 million at March 31, 2013 and approximately 45.0 million shares of Chimera at a fair value of approximately $117.4 million at December 31, 2012. At March 31, 2013 and December 31, 2012, the investment in Chimera had an unrealized gain of $4.6 million and an unrealized loss of $21.5 million, respectively. The Company owned approximately 9.5 million shares of CreXus at a fair value of approximately $124.1 million at March 31, 2013 and approximately 9.5 million shares of CreXus at a fair value of approximately $116.7 million at December 31, 2012. At March 31, 2013 and December 31, 2012, the investment in CreXus had an unrealized loss of $1.4 million and an unrealized loss of $8.7 million, respectively.

The Company has evaluated the near-term prospects of its investment in affiliates in relation to the severity and length of time of the impairment. Based on this evaluation, management has determined that its investment in affiliates is not considered to be other-than-temporarily impaired as of March 31, 2013 and December 31, 2012 as the Company has the intent and ability to retain its investments for a period of time sufficient to allow for any anticipated recovery in market value.